Trial Information

Summary: A dose ranging study of study drug in daily doses for 4 weeks in paients with Overactive Bladder Syndrome

This study is designed to evaluate the dose-response relationship of study drug on efficacy in patients with Overactive Bladder Syndrome over a 4 week treatment duration.

Patient Inclusion Criteria

• Males or females age 18 to 80 years with symptoms of Overactive Bladder based on urgency with or without incontinence and frequency

Patient Exclusion Criteria

• Patients with clinically significant bladder obstruction.
• Patients with stress incontinence
• Patients with neurogenic incontinence
• Patients with significant urogenital disease such as urinary tract infection, interstitial cystitis
• Patients with bladder cancer, prostate cancer or chronic prostititis either under current treatment of diagnosed in the past 6 months.

For more information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.